Easily differentiate between SARS-CoV-2 and Influenza A/B with a truly integrated test requiring a single sample to optimise patient care.
Symptoms of COVID-19, influenza and other respiratory diseases are similar. It can be difficult for HCPs to make decisions based on signs and symptoms alone. If patients are left undiagnosed, it may result in community spread. For HCPs it is vital to rapidly identify an infection with a highly contagious virus such as SARS-CoV-2 or Influenza A or B.
Rapid results also give patients the knowledge and reassurance when symptoms are inconclusive.
Purpose
Isolation measures help prevent an infectious individual from spreading the virus to others.
Beneficiary
Symptomatic patients and their surroundings.
Sites
Hospitals, clinics, physician offices, test hubs, public locations, occupational medicine, pharmacies and others.
Caveat
Negative results do not exclude other viral or bacterial infections.
With similar symptoms for SARS-CoV-2 and Influenza A/B, HCPs need to quickly determine which infection is present.
The SARS-CoV-2 & Flu A/B Rapid Antigen Test easily differentiates between SARS-CoV-2 and Influenza A/B with a single sample.
Purpose
For fast triaging of symptomatic patients and to distinguish between SARS-CoV-2 and Influenza A and B with a single sample.
Beneficiary
Symptomatic patients and their surroundings.
Sites
Hospitals, clinics, physician offices, test hubs, public locations, occupational medicine, pharmacies and others.
Caveat
Triage ≠ diagnosis
Early, widespread and reliable testing for COVID-19 and flu is more important than ever to help HCPs diagnose and differentiate between the SARS-CoV-2 and influenza A/B viruses, to make informed decisions and optimise patient care.
Roche is committed to delivering a leading antiviral and immunomodulatory therapeutics portfolio for COVID-19 and Flu.
When taking the appropriate antiviral treatments early in the disease progress,* it can help to reduce the time people experience COVID-19 or flu symptoms.
*<48 hours after symptom onset
Purpose
Proceed to treatment options as early as possible when medication is most effective.
Beneficiary
Patients in an early disease stage (<48 hours after symptom onset).
Sites
Hospitals, clinics, physician offices, test hubs, public locations, occupational medicine, pharmacies and others.
Caveat
Negative results do not exclude other viral or bacterial infections.
During the respiratory season, various respiratory viruses may emerge, placing significant strain on healthcare systems and testing capacities when numbers surge simultaneously.
Rapid testing is a viable option to help get outbreaks under control by introducing widespread testing without the need for lab infrastructure or instruments.
Test capacities can be scaled up significantly, supporting decentralised testing strategies.
In highly centralised healthcare systems or rural areas, testing can fill the gap whenever it is more efficient to bring the test to the patient as opposed to bringing patients to testing facilities.
Purpose
Accessible testing outside the lab to support testing strategies and scale up capacities wherever and whenever it is needed most.
Beneficiary
Remote locations, low infrastructure areas, governments, healthcare systems and individuals
Sites
Hospitals, clinics, physician offices, test hubs, public locations, occupational medicine, pharmacies and others reaching their testing capacity limit during flu season.
Caveat
Faster results are more important than lower performance compared to lab testing.
Rapid answers, combined
This rapid test expands the virus detection capacities, decentralises testing and improves the testing experience while ensuring optimal patient care by supporting informed decisions on an antiviral treatment definition.
We look forward to hearing from you.
